Human Genome Epidemiology Literature Finder
Records 1 - 5 (of 5 Records) |
Query Trace: Edema and BRAF[original query] |
---|
Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. Clinical cancer research : an official journal of the American Association for Cancer Research 2012 Jan 18 (2): 555-67. Kirkwood John M, Bastholt Lars, Robert Caroline, Sosman Jeff, Larkin James, Hersey Peter, Middleton Mark, Cantarini Mireille, Zazulina Victoria, Kemsley Karin, Dummer Reinha |
Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements. Clinical cancer research : an official journal of the American Association for Cancer Research 2012 Apr 18 (7): 2056-65. Hayes D Neil, Lucas Amy S, Tanvetyanon Tawee, Krzyzanowska Monika K, Chung Christine H, Murphy Barbara A, Gilbert Jill, Mehra Ranee, Moore Dominic T, Sheikh Arif, Hoskins Janelle, Hayward Michele C, Zhao Ni, O'Connor Wendi, Weck Karen E, Cohen Roger B, Cohen Ezra E |
Phase II Study of a Non-Platinum-Containing Doublet of Paclitaxel and Pemetrexed with Bevacizumab as Initial Therapy for Patients with Advanced Lung Adenocarcinomas. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2016 Mar . Pietanza Catherine M, Hellmann Matthew D, Fiore John J, Smith-Marrone Stephanie, Basch Ethan M, Schwartz Lawrence H, Ginsberg Michelle S, Shouery Marwan, Newman Samantha K, Shaw Mary, Rogak Lauren J, Lash Alex, Hilden Patrick, Kris Mark |
Clinical and biological significance of adamantinomatous craniopharyngioma with CTNNB1 mutation. Journal of neurosurgery 2018 Jul 1-10. Hara Takuma, Akutsu Hiroyoshi, Takano Shingo, Kino Hiroyoshi, Ishikawa Eiichi, Tanaka Shuho, Miyamoto Hidetaka, Sakamoto Noriaki, Hattori Keiichiro, Sakata-Yanagimoto Mamiko, Chiba Shigeru, Hiyama Takashi, Masumoto Tomohiko, Matsumura Aki |
Clinical, Morphological, and Molecular Study on Grade 2 and 3 Pleomorphic Xanthoastrocytoma. Current oncology (Toronto, Ont.) 2023 2 30 (2): 2405-2416. Zhang Hui, Ma Xiao-Jing, Xiang Xue-Ping, Wang Qi-Yuan, Tang Jin-Long, Yu Xiao-Yan, Xu Jing-Ho |
- Page last reviewed:Feb 1, 2024
- Page last updated:Apr 16, 2024
- Content source: